Jupiter Life Line Hospitals Ltd
Jupiter Life Line Hospitals Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Jupiter Life Line Hospitals anticipates strong long-term demand growth, especially in new markets like Dombivali, due to lack of supply and dense population. Mature hospitals are expected to maintain EBITDA margins in the mid-20% range.
From Jupiter Life Line Hospitals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Jupiter Life Line Hospitals anticipates strong long-term demand growth, especially in new markets like Dombivali, due to lack of supply and dense population.
- ARPOB (Average Revenue Per Occupied Bed) improved ~15% in H1 FY26 driven by case mix optimization and rate revisions.
- New hospitals (Dombivali, South Pune, Mira Road) are under development, expected to augment future revenue streams.
- Dombivali Hospital is expected to start operations by Q1 FY27; initial years may see lower ARPOB and occupancy, with break-even likely by year two at ~40-45% occupancy.
- Existing hospitals show steady or increasing occupancy (e.g., Thane plateaued mid-70%, Pune approaching 70%, Indore rising after bed additions).
2 more points from Jupiter Life Line Hospitals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Jupiter Life Line Hospitals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current CAPEX incurred in H1 FY26 is approximately Rs. 110 crores, primarily for new projects.
- Three key projects underway: Dombivali Hospital (on track to start Q1 next financial year), South Pune Hospital (construction started in Q3 FY26), and Mira Road Hospital (currently at architectural drawing stage).
- The company's strategy involves completing these projects using internal accruals and existing resources without requiring significant additional debt.
- No live inorganic acquisition deals in progress, but the company remains open to sensible opportunities in Western India, including Maharashtra, Gujarat, and Madhya Pradesh.
2 more points from Jupiter Life Line Hospitals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jupiter Life Line Hospitals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- There is no explicit mention of a current or expected order book or pending orders for Jupiter Life Line Hospitals Limited in the provided transcript.
- The company is focused on organic growth with ongoing discussions for new hospital projects but no concrete land acquisition or expansion plans are finalized yet (Page 11).
- Three hospital projects are underway: Dombivali (near completion, expected operational in Q1 next financial year), South Pune (construction commenced in Q3 FY26), and Mira Road (architectural planning stage) (Page 3).
2 more points from Jupiter Life Line Hospitals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Jupiter Life Line Hospitals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹388 Cr, net profit ₹50 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jupiter Life Line Hospitals Ltd's management said in earlier quarters
Others in Healthcare Services this season
- Maitreya Medica. (Q2 FY26)
23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medica.'s Q2 FY26 investor presentation — and how it ranks against sector peers.
- Metropolis Healt (Q2 FY26)
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
- 3B Blackbio (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
- Unihealth Hosp (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
Arthneeti Pro · Annual
Jupiter Life Line Hospitals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jupiter Life Line Hospitals Ltd Q2 FY26 results?
Jupiter Life Line Hospitals anticipates strong long-term demand growth, especially in new markets like Dombivali, due to lack of supply and dense population. Mature hospitals are expected to maintain EBITDA margins in the mid-20% range.
What is Jupiter Life Line Hospitals Ltd share price analysis?
Jupiter Life Line Hospitals Ltd currently shows a neutral. The stock trades at a P/E of 54.1 with a market cap of ₹10,351 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jupiter Life Line Hospitals Ltd planning capital expenditure?
Current CAPEX incurred in H1 FY26 is approximately Rs.
Keep Jupiter Life Line Hospitals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.